American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 8(62), 2018
DOI: 10.1128/aac.00766-18
Full text: Download
Morbidity and mortality resulting from influenza-like disease are a threat, especially for older adults. To improve case management, next-generation broad-spectrum antiviral therapeutics that are efficacious against major drivers of influenza-like disease, including influenza viruses and respiratory syncytial virus (RSV), are urgently needed.